Tuesday, BioXcel Therapeutics, Inc. (BTAI) announced the termination of its proposed public offering of $60 million in common stock which was previously announced on February 8, 2024.
BioXcel Therapeutics, Inc. (BTAI), a biopharmaceutical company focused on neuroscience and immuno-oncology, announced Tuesday positive overall survival or OS data from its Phase 2 trial of BXCL701 in combination with KEYTRUDA (pembrolizumab) in patients with small cell neuroendocrine prostate cancer or SCNC.
Presenter SpeechCorinne Jenkins Great. Welcome, everyone, and welcome, especially to the team from BioXcel Therapeutics. Today, we have Vimal Mehta, CEO; Rob Risinger, CMO; and then we ve got Matt. | June 14, 2023